BioSpace News Archive

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.

Elite Pharmaceuticals, Inc. announced today that the first quarter financial results of the 2024 fiscal year will be released on Monday, August 14, 2023.

Protagonist Therapeutics today announced it has received approximately $34.4 million in proceeds from the exercise of warrants to purchase 2.75 million shares of the Company’s Common Stock.

Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 9th of August that an Investigational New Drug (IND) application has been approved by the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery technology, DegradaBALL ® on 21st of July.

Century Therapeutics, Inc. today reported financial results and business highlights for the second quarter ended June 30, 2023.

CalciMedica Inc. today announced that its ongoing CARPO trial, a Phase 2b trial evaluating Auxora™ for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS), was expanded to clinical research sites in India and that the first patient has been enrolled there.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing.

Eyenovia, Inc. today announced management will deliver a presentation and participate in a panel discussion at the H.C. Wainwright 3rd Annual Ophthalmology Day, which is taking place virtually on August 16, 2023.

Pliant Therapeutics, Inc. today announced the initiation of BEACON-IPF, a Phase 2b clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of positive preliminary efficacy results from its Phase 1/2 clinical study of DARE-HRT1 in healthy postmenopausal women.